Efficacy and safety of active vitamin D supplementation in chronic spontaneous urticaria patients
- Citation:
- Mohamed, A. A., M. S. Hussein, E. M. Salah, A. Eldemery, M. M. Darwish, D. M. Ghaith, R. A. Attala, and R. E. Borolossy, Efficacy and safety of active vitamin D supplementation in chronic spontaneous urticaria patients, , vol. 33, no. 1, pp. 427–432, 2022.
Abstract:
Chronic spontaneous urticaria ({CSU}) is a common skin disorder affecting negatively patients’ lives. Vitamin D deficiency has been reported to be associated to many allergic skin disorders. This study aimed to evaluate the association between the serum level of 25 hydroxy vitamin D and {CSU} and to assess the efficacy and safety of active vitamin D in management of {CSU}. The study was conducted on 77 patients with {CSU} and 67 healthy controls, then the 77 {CSU} patients were randomized to either the study group that received 0.25 µg alfacalcidol daily or the placebo group that received oral placebo for 12 weeks. Serum 25({OH}) D was significantly lower in {CSU} as compared to healthy controls and was negatively correlated to the urticarial severity. After alfacalcidol administration, the study group showed significant higher level of 25({OH}) D compared to the placebo group. In addition, the mean serum level of {IL}6, {hsCRP} and {TNFα} significantly decreased in the study group in comparison to the placebo group and as compared to their baseline results. Vitamin D deficiency is more common in {CSU} patients as compared to healthy people and hence, alfacalcidol might have a beneficial role as add on therapy in {CSU} management with no reported side effects.
Notes:
Publisher: Taylor & Francis \_eprint: https://doi.org/10.1080/09546634.2020.1762838